About: Procalcitonin Accurately Identifies Hospitalized Children With Low Risk of Bacterial Community-Acquired Pneumonia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Procalcitonin Accurately Identifies Hospitalized Children With Low Risk of Bacterial Community-Acquired Pneumonia Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Procalcitonin Accurately Identifies Hospitalized Children With Low Risk of Bacterial Community-Acquired Pneumonia
Creator	Edwards, Kathryn Ampofo, Krow Stockmann, Chris Bramley, Anna Jain, Seema Killpack, Jarrett Anderson, Evan Blaschke, Anne Arnold, Sandra Grijalva, Carlos Mccullers, Jonathan Pavia, Andrew Self, Wesley Williams, Derek Wunderink, Richard
Source	Medline; PMC
abstract	BACKGROUND: Lower procalcitonin (PCT) concentrations are associated with reduced risk of bacterial community-acquired pneumonia (CAP) in adults, but data in children are limited. METHODS: We analyzed serum PCT concentrations from children hospitalized with radiographically confirmed CAP enrolled in the Centers for Disease Control and Prevention’s Etiology of Pneumonia in the Community (EPIC) Study. Blood and respiratory specimens were tested using multiple pathogen detection methods for typical bacteria (eg, Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus), atypical bacteria (Mycoplasma pneumoniae and Chlamydophila pneumoniae), and respiratory viruses. Multivariable regression was used to assess associations between PCT concentrations and etiology and severity. RESULTS: Among 532 children (median age, 2.4 years; interquartile range [IQR], 1.0–6.3), patients with typical bacteria had higher PCT concentrations (±viruses; n = 54; median, 6.10; IQR, 0.84–22.79 ng/mL) than those with atypical bacteria (±viruses; n = 82; median, 0.10; IQR, 0.06–0.39 ng/mL), viral pathogens only (n = 349; median, 0.33; IQR, 0.12–1.35 ng/mL), or no pathogen detected (n = 47; median, 0.44; IQR, 0.10–1.83 ng/mL) (P < .001 for all). No child with PCT <0.1 ng/mL had typical bacteria detected. Procalcitonin <0.25 ng/mL featured a 96% negative predictive value (95% confidence interval [CI], 93–99), 85% sensitivity (95% CI, 76–95), and 45% specificity (95% CI, 40–50) in identifying children without typical bacterial CAP. CONCLUSIONS: Lower PCT concentrations in children hospitalized with CAP were associated with a reduced risk of typical bacterial detection and may help identify children who would not benefit from antibiotic treatment.
has issue date	2017-02-03(xsd:dateTime)
bibo:doi	10.1093/jpids/piw091
bibo:pmid	28158460
has license	bronze-oa
sha1sum (hex)	3d8d47d2555eb338580a3f1ec86143cf4340034d
schema:url	https://doi.org/10.1093/jpids/piw091
resource representing a document's title	Procalcitonin Accurately Identifies Hospitalized Children With Low Risk of Bacterial Community-Acquired Pneumonia
has PubMed Central identifier	PMC6251689
has PubMed identifier	28158460
schema:publication	Journal of the Pediatric Infectious Diseases Society
resource representing a document's body	covid:3d8d47d2555eb338580a3f1ec86143cf4340034d#body_text
is schema:about of	named entity 'LOW RISK' named entity 'ASSOCIATED WITH' named entity 'LOWER' named entity 'RISK OF' named entity 'BUT' covid:arg/3d8d47d2555eb338580a3f1ec86143cf4340034d named entity 'SOCIETY' named entity 'RISK OF' named entity 'BACTERIAL COMMUNITY' named entity 'JOURNAL ' named entity 'CONCENTRATIONS' named entity 'COMMUNITY-ACQUIRED PNEUMONIA' named entity 'BACTERIAL COMMUNITY' named entity 'CHILDREN' named entity 'REDUCED' named entity 'BACKGROUND' named entity 'HOSPITALIZED CHILDREN' named entity 'LIMITED' named entity 'PROCALCITONIN' named entity 'ADULTS' named entity 'DATA' named entity 'PEDIATRIC INFECTIOUS DISEASES' named entity 'COMMUNITY-ACQUIRED PNEUMONIA' named entity 'PROCALCITONIN' named entity 'concentrations' named entity 'Community-Acquired Pneumonia' named entity 'antibiotic' named entity 'viral pathogen' named entity 'bronchoalveolar lavage' named entity 'high-quality' named entity 'Salt Lake City' named entity 'clinical guidelines' named entity 'radiographic' named entity 'ICU' named entity 'radiographically' named entity 'pathogens' named entity 'CDC' named entity 'Procalcitonin' named entity 'PhD' named entity 'bioMérieux' named entity 'ICU' named entity 'bacterial disease' named entity 'ng/mL' named entity 'antibiotic therapy' named entity 'ng/mL' named entity 'mountain biker' named entity 'empyema' named entity '95% CI' named entity 'Diagnostic testing' named entity 'antibiotic therapy' named entity 'atypical bacteria' named entity 'pathogen' named entity 'LRTI' named entity 'cross-validation' named entity 'Procalcitonin' named entity 'aspirates' named entity '95% CI' named entity 'bacterial pathogen' named entity 'ng/mL' named entity 'coronavirus' named entity 'biomarkers' named entity 'Nashville, Tennessee' named entity 'oropharyngeal' named entity 'molecular methods' named entity 'parainfluenza virus' named entity 'laboratory testing' named entity 'Sweden'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software